Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

Presentation TCT India 2025

Lifetime Management: What to Consider When Deciding Between TAVI and SAVR?

July 25, 2025

Presentation EuroPCR 2024

First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2

Presenter: Ole De Backer

May 15, 2024

Presentation Miami Valves 2024

Valve in Valve for SAVR Degeneration with Aortic Insufficiency & Shock

Presenter: Som Bailey

February 03, 2024

Presentation Miami Valves 2024

Advanced Planning and Simulation for Valve in Valve TAVR and SAVR

Presenter: Nicolas M. Van Mieghem

February 01, 2024

Presentation STS 2024

Guidelines versus Practice: A Statewide Survival Analysis of SAVR versus TAVR in Patients Aged < 60 Years

Presenter: Jad Malas

January 27, 2024

Presentation Miami Valves 2022

Catheter Based Treatment of Structural Heart Disease Year in Review 2022

Presenter: Eduardo de Marchena

February 03, 2022

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

Presentation

In-hospital Outcomes and Readmissions forValve-in-Valve TAVR vs Surgical Redo

June 01, 2020

Presentation Live Valves 2019

Valve Guidelines: How Effective are They?

Presenter: Volkmar Falk

December 10, 2019

Presentation Live Valves 2019

TAVI: Which Prosthesis for Which Patient?

Presenter: Holger Thiele

December 10, 2019

Presentation Live Valves 2019

Optimal hemodynamics: TAVI or SAVR?

Presenter: Lars Sondergaard

December 10, 2019

Presentation Live Valves 2019

Failed Aortic Valve Bioprostheses: Valve-in-Valve or Redo-SAVR?

Presenter: Danny Dvir

December 10, 2019

Presentation Controversies and Advances 2019

Should TAVR Be Standard for Bicuspid Aortic Stenosis, Or Do We Need a Randomized Clinical Trial?

Presenter: Raj R. Makkar

November 15, 2019

Presentation EuroPCR 2019

Prosthetic valve endocarditis after transcatheter or surgical AVR with a bioprosthesis Results from the FinnValve registry

Presenter: Noriaki Moriyama

May 21, 2019

Presentation SIF 2019

TAVR for Aortic Insufficiency

Presenter: Steven J Yakubov

March 30, 2019

Presentation SIF 2019

My Prediction on TAVR in Low Risk Patients

Presenter: Kendra J. Grubb

March 30, 2019

Presentation CIT 2019

Status of indication of TAVR versus SAVR in low-intermediate risk patients

Presenter: Thomas Modine

March 28, 2019

Presentation ACC 2019

Primary Results From the Evolut Low Risk Trial

Presenter: Michael J. Reardon

March 17, 2019

Presentation JIM 2019

When and how to perform valvuloplasty: Experience with Valver

Presenter: Nicola Corcione

February 15, 2019

Presentation

Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Low Risk

February 06, 2019

Advertisement

Lifetime Management: What to Consider When Deciding Between TAVI and SAVR?

First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2

Valve in Valve for SAVR Degeneration with Aortic Insufficiency & Shock

Advanced Planning and Simulation for Valve in Valve TAVR and SAVR

Guidelines versus Practice: A Statewide Survival Analysis of SAVR versus TAVR in Patients Aged < 60 Years

Catheter Based Treatment of Structural Heart Disease Year in Review 2022

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

In-hospital Outcomes and Readmissions forValve-in-Valve TAVR vs Surgical Redo

Valve Guidelines: How Effective are They?

TAVI: Which Prosthesis for Which Patient?

Optimal hemodynamics: TAVI or SAVR?

Failed Aortic Valve Bioprostheses: Valve-in-Valve or Redo-SAVR?

Should TAVR Be Standard for Bicuspid Aortic Stenosis, Or Do We Need a Randomized Clinical Trial?

Prosthetic valve endocarditis after transcatheter or surgical AVR with a bioprosthesis Results from the FinnValve registry

TAVR for Aortic Insufficiency

My Prediction on TAVR in Low Risk Patients

Status of indication of TAVR versus SAVR in low-intermediate risk patients

Primary Results From the Evolut Low Risk Trial

When and how to perform valvuloplasty: Experience with Valver

Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Low Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content